share_log

Bank of Nova Scotia Reduces Position in Bristol-Myers Squibb (NYSE:BMY)

Bank of Nova Scotia Reduces Position in Bristol-Myers Squibb (NYSE:BMY)

豐業銀行減持百時美施貴寶(紐約證券交易所代碼：BMY)
Financial News Live ·  2022/08/13 01:01

Bank of Nova Scotia lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 81.2% during the 1st quarter, Holdings Channel reports. The firm owned 316,586 shares of the biopharmaceutical company's stock after selling 1,363,989 shares during the quarter. Bank of Nova Scotia's holdings in Bristol-Myers Squibb were worth $23,120,000 as of its most recent filing with the Securities and Exchange Commission.

據控股頻道報道，豐業銀行在第一季度減持了百時美施貴寶(紐約證券交易所代碼：BMY-GET評級)81.2%的股份。該公司在本季度出售了1,363,989股後，持有這家生物製藥公司316,586股股票。根據百時美施貴寶最近提交給美國證券交易委員會的文件，豐業銀行持有的百時美施貴寶價值2312萬美元。

Several other large investors also recently bought and sold shares of the stock. Cahaba Wealth Management Inc. boosted its holdings in shares of Bristol-Myers Squibb by 2.5% in the 1st quarter. Cahaba Wealth Management Inc. now owns 5,391 shares of the biopharmaceutical company's stock valued at $405,000 after acquiring an additional 132 shares during the last quarter. MV Capital Management Inc. boosted its holdings in shares of Bristol-Myers Squibb by 10.7% in the 1st quarter. MV Capital Management Inc. now owns 1,391 shares of the biopharmaceutical company's stock valued at $102,000 after acquiring an additional 135 shares during the last quarter. Sanders Morris Harris LLC boosted its holdings in shares of Bristol-Myers Squibb by 0.3% in the 1st quarter. Sanders Morris Harris LLC now owns 40,501 shares of the biopharmaceutical company's stock valued at $2,958,000 after acquiring an additional 137 shares during the last quarter. Bernardo Wealth Planning LLC boosted its holdings in shares of Bristol-Myers Squibb by 4.3% in the 1st quarter. Bernardo Wealth Planning LLC now owns 3,389 shares of the biopharmaceutical company's stock valued at $247,000 after acquiring an additional 139 shares during the last quarter. Finally, Stiles Financial Services Inc boosted its holdings in shares of Bristol-Myers Squibb by 2.3% in the 1st quarter. Stiles Financial Services Inc now owns 6,368 shares of the biopharmaceutical company's stock valued at $465,000 after acquiring an additional 141 shares during the last quarter. Hedge funds and other institutional investors own 73.07% of the company's stock.

其他幾家大型投資者最近也買賣了該股的股票。Cahaba Wealth Management Inc.在第一季度增持了2.5%的百時美施貴寶股票。卡哈巴財富管理公司(Cahaba Wealth Management Inc.)目前持有這家生物製藥公司5,391股股票，價值40.5萬美元，該公司在上個季度增持了132股股票。MV Capital Management Inc.在第一季度增持了10.7%的百時美施貴寶股票。MV Capital Management Inc.現在持有這家生物製藥公司1,391股股票，價值10.2萬美元，該公司在上個季度增持了135股。桑德斯·莫里斯·哈里斯有限責任公司在第一季度將百時美施貴寶的股票持有量增加了0.3%。桑德斯·莫里斯·哈里斯有限責任公司(Sanders Morris Harris LLC)現在擁有這家生物製藥公司40,501股股票，價值2,958,000美元，此前在上個季度又購買了137股。Bernardo Wealth Program LLC在第一季度增持了4.3%的百時美施貴寶股票。貝爾納多財富規劃有限責任公司現在擁有3389股這家生物製藥公司的股票，價值24.7萬美元，在上個季度額外購買了139股。最後，斯泰爾斯金融服務公司在第一季度增持了2.3%的百時美施貴寶股票。斯泰爾斯金融服務公司現在擁有6,368股這家生物製藥公司的股票，價值465,000美元，在上個季度額外購買了141股。對衝基金和其他機構投資者持有該公司73.07%的股票。

Get
到達
Bristol-Myers Squibb
百時美施貴寶
alerts:
警報：

Analyst Upgrades and Downgrades

分析師升級和下調評級

BMY has been the subject of several analyst reports. Barclays boosted their target price on shares of Bristol-Myers Squibb from $66.00 to $68.00 in a research note on Monday, May 2nd. Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $65.00 to $70.00 and gave the stock an "equal weight" rating in a research report on Tuesday, May 17th. Truist Financial upped their target price on shares of Bristol-Myers Squibb from $76.00 to $81.00 in a report on Monday, May 2nd. Bank of America upped their target price on shares of Bristol-Myers Squibb from $78.00 to $80.00 and gave the stock a "buy" rating in a report on Monday, June 6th. Finally, BMO Capital Markets upped their target price on shares of Bristol-Myers Squibb from $87.00 to $92.00 in a report on Monday, May 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $75.57.

BMY一直是幾份分析師報告的主題。巴克萊在5月2日星期一的一份研究報告中將百時美施貴寶的股票目標價從66.00美元上調至68.00美元。在5月17日週二的一份研究報告中，富國銀行將百時美施貴寶的股票目標價從65.00美元上調至70.00美元，並給予該股“同等權重”的評級。在5月2日星期一的一份報告中，Truist Financial將百時美施貴寶的股票目標價從76.00美元上調至81.00美元。在6月6日週一的一份報告中，美國銀行將百時美施貴寶的股票目標價從78.00美元上調至80.00美元，並給予該股“買入”評級。最後，蒙特利爾銀行資本市場在5月2日星期一的一份報告中將百時美施貴寶的股票目標價從87.00美元上調至92.00美元。一位研究分析師對該股的評級為賣出，4位分析師發佈了持有評級，7位分析師發佈了買入評級，一位分析師給予了該公司強烈的買入評級。根據MarketBeat.com的數據，該公司的平均評級為“中等買入”，平均目標價為75.57美元.

Insiders Place Their Bets

內部人士下注

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of the stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $74.04, for a total transaction of $2,221,200.00. Following the completion of the transaction, the chief executive officer now owns 551,104 shares of the company's stock, valued at $40,803,740.16. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Giovanni Caforio sold 30,000 shares of the stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $74.04, for a total transaction of $2,221,200.00. Following the sale, the chief executive officer now owns 551,104 shares of the company's stock, valued at $40,803,740.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sandra Leung sold 65,000 shares of the stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $74.89, for a total transaction of $4,867,850.00. Following the sale, the executive vice president now directly owns 308,627 shares in the company, valued at approximately $23,113,076.03. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.
在百時美施貴寶的其他消息中，首席執行官喬瓦尼·卡福裏奧在6月13日星期一的交易中出售了30,000股該股。這些股票以74.04美元的平均價格出售，總成交金額為2221,200.00美元。交易完成後，首席執行官現在擁有551,104股公司股票，價值40,803,740.16美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過以下鏈接獲得。在其他新聞方面，首席執行官喬瓦尼·卡福裏奧在6月13日星期一的交易中出售了30,000股該公司股票。這些股票以74.04美元的平均價格出售，總成交金額為2221,200.00美元。出售後，這位首席執行官現在擁有551,104股公司股票，價值40,803,740.16美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，用户可以通過美國證券交易委員會網站查看該文件。此外，執行副總裁樑淑儀在6月6日星期一的交易中出售了6.5萬股該股。該股以74.89美元的平均價格出售，總成交金額為4867,850.00美元。出售後，執行副總裁總裁現在直接持有該公司308,627股股份，價值約23,113,076.03美元。此次拍賣的披露信息可在此處找到。該股目前由內部人士持有0.09%的股份。

Bristol-Myers Squibb Trading Down 0.5 %

百時美施貴寶股價下跌0.5%

Shares of BMY stock opened at $74.46 on Friday. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.44 and a quick ratio of 1.34. The firm has a market cap of $158.99 billion, a PE ratio of 24.74, a price-to-earnings-growth ratio of 1.59 and a beta of 0.40. The company has a 50-day moving average of $74.94 and a two-hundred day moving average of $73.00. Bristol-Myers Squibb has a 1-year low of $53.22 and a 1-year high of $80.59.

上週五，BMY股票開盤報74.46美元。該公司的債務權益比為1.14，流動比率為1.44，速動比率為1.34。該公司市值為1,589.9億美元，市盈率為24.74倍，市盈率為1.59倍，貝塔係數為0.40。該公司的50日移動均線切入位在74.94美元，200日移動均線切入位在73.00美元。百時美施貴寶的一年低點為53.22美元，一年高位為80.59美元。

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its earnings results on Wednesday, July 27th. The biopharmaceutical company reported $1.93 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.14. The company had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.50 billion. Bristol-Myers Squibb had a net margin of 14.04% and a return on equity of 49.31%. Bristol-Myers Squibb's revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.93 earnings per share. On average, analysts predict that Bristol-Myers Squibb will post 7.53 EPS for the current year.

百時美施貴寶(紐約證券交易所代碼：BMY-GET評級)最近一次公佈收益結果是在7月27日星期三。這家生物製藥公司公佈本季度每股收益為1.93美元，比普遍預期的1.79美元高出0.14美元。該公司本季度營收為118.9億美元，而分析師預期為115億美元。百時美施貴寶的淨利潤率為14.04%，股本回報率為49.31%。與去年同期相比，百時美施貴寶的收入增長了1.6%。去年同一季度，該公司公佈的每股收益為1.93美元。分析師平均預測，百時美施貴寶本年度每股收益將達到7.53歐元。

Bristol-Myers Squibb Announces Dividend

百時美施貴寶宣佈分紅

The business also recently announced a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Friday, July 1st were paid a dividend of $0.54 per share. This represents a $2.16 annualized dividend and a yield of 2.90%. The ex-dividend date of this dividend was Thursday, June 30th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 71.76%.

該公司最近還宣佈了季度股息，股息於8月1日(星期一)支付。7月1日(星期五)登記在冊的股東獲得了每股0.54美元的股息。這意味着年化股息為2.16美元，收益率為2.90%。本次股息除息日期為6月30日星期四。百時美施貴寶的股息支付率(DPR)目前為71.76%。

Bristol-Myers Squibb Profile

百時美施貴寶簡介

(Get Rating)

(獲取評級)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

百時美施貴寶公司在全球發現、開發、許可、製造和營銷生物製藥產品。它提供血液學、腫瘤學、心血管學、免疫學、纖維化、神經科學和新冠肺炎疾病的產品。該公司的產品包括治療多發性骨髓瘤的口服免疫調節藥物Revlimid；用於降低NVAF中風/系統性栓塞風險和治療DVT/PE的口服抑制劑Eiquis；用於抗癌適應症的Opdivo；用於多發性骨髓瘤患者的Pomalyst/Imnovid；以及用於成人活動期RA和牛皮癬關節炎的Orencia。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
  • Can You Guess Which EV Stock Is Beating Tesla ?
  • Look at Honeywell for a Steady and Diversified Stock
  • Why Invest in High-Yield Dividend Stocks?
  • Find and Profitably Trade Stocks at 52-Week Lows
  • Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
  • 免費獲取StockNews.com關於百時美施貴寶(BMY)的研究報告
  • 你能猜到哪個電動車股票打敗了特斯拉嗎？
  • 霍尼韋爾看好穩定和多元化的股票
  • 為什麼要投資高收益股利股票？
  • 找到並獲利於52周低點的股票交易
  • 迪士尼(NYSE：DIS)的股票剛剛給了投資者一個巨大的信號

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).

想看看其他對衝基金持有哪些BMY嗎？訪問HoldingsChannel.com獲取百時美施貴寶(紐約證券交易所代碼：BMY-GET Rating)的最新13F備案文件和內幕交易信息。

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

接受百時美施貴寶日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對百時美施貴寶及相關公司評級的每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論